TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03101826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening Project Protocol
Description: The filtered music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
Study: NCT04000542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Intervention
Description: The pharmacist will record a 30 second rhythm strip from patients using the KardiaMobile device and calculate the QTc interval using the Bazett calculation formula. The pharmacist will discuss the result with the patient and if necessary, will contact the prescriber to effect a medication change. If the QTc interval is greater than the 99th percentile, (470 ms for males, 480 ms for females) the pharmacist must contact the prescriber. The pharmacist will record any prescription changes which resulted from the intervention and the prescriber response. The pharmacist will email the rhythm strip (with study participation number) to a secure email at the Northeast Iowa Family Practice Center (NEIFPC). Rhythm strips will be archived for future potential research evaluation in a secure, electronic file.
Study: NCT04318522

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulator
Description: Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation device that can excite or inhibit the brain activity depending on the stimulation protocol. It has mainly two variants including conventional c-tDCS and High-Definition HD-tDCS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulator
Description: Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation device that can excite or inhibit the brain activity depending on the stimulation protocol. It has mainly two variants including conventional c-tDCS and High-Definition HD-tDCS.
Study: NCT04151160

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound measurements
Description: i. Ultrasound images will be obtained using a commercial, high frequency, linear Philips ultrasound probe attached to small, portable tablet. This tablet will have the capability of transferring the saved images to the secure MuscleSound cloud-based server.

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound measurements
Description: i. Ultrasound images will be obtained using a commercial, high frequency, linear Philips ultrasound probe attached to small, portable tablet. This tablet will have the capability of transferring the saved images to the secure MuscleSound cloud-based server.
Study: NCT02556294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-acceptance based intervention
Description: The intervention will consist of HIV/STI counseling and testing as well as individual counseling sessions and group sessions. The primary focus of the group sessions are to help foster self-acceptance by the support from the group, as well as learn skills to reduce distress and HIV risk. The primary purpose of the individual sessions is to help develop and implement an individualized plan for HIV risk reduction, and, as needed and available, linkage to other services.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HIV/STI counseling and testing
Description: The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV/STI counseling and testing
Description: The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.
Study: NCT02706834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-828 placebo-matching oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-828 placebo-matching oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-828 placebo-matching oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-828 placebo-matching oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-828 placebo-matching oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-828 placebo-matching oral solution
Study: NCT04315025

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)
Description: Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)
Description: Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conditioned Medium (CM)
Description: Conditioned Medium (CM) injected by peribulbar

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conditioned Medium (CM)
Description: Conditioned Medium (CM) injected by peribulbar
Study: NCT01030978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright Bodies Healthy Lifestyle Program
Description: Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Subjects will be given basic instruction by clinical provider and goals will be followed up every 3 months.
Study: NCT01138930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: 1.5g daily for 3 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo daily
Study: NCT02664701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline evaluation with a psychiatrist
Description: Baseline data and questionnaires are established.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline evaluation with a psychiatrist
Description: Baseline data and questionnaires are established.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual supportive therapy
Description: 6 sessions of individual supportive therapy with a psychologist, 1 session per week for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group therapy
Description: 6 sessions of cognitive behavioural group therapy with a psychologist, 1 session per week for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluations with a psychiatrist
Description: Evaluation withs a psychiatrist in the 10 days following the end of psychotherapy, then at 3, 6, 9, and 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluations with a psychiatrist
Description: Evaluation withs a psychiatrist in the 10 days following the end of psychotherapy, then at 3, 6, 9, and 12 months.
Study: NCT03221062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser en Bloc Resection
Description: Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser en Bloc Resection
Description: Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser en Bloc Resection
Description: Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection
Study: NCT00421525

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: milatuzumab
Description: twice weekly dosing for 4 weeks, total of 8 doses
Study: NCT02768948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan during 6 months
Description: telmisartan during 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan during 6 months
Description: Losartan during 6 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample
Study: NCT02176421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOLBELLA® with lidocaine
Description: VOLBELLA® with lidocaine administered to correct skin depression during initial treatment and optional top-up treatment 14 days later.
Study: NCT03430063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDREGN2810
Description: Standard dose intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDREGN2810/ipi
Description: Combination therapy dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDREGN2810
Description: High dose IV
Study: NCT02268617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Walking
Description: Following instructions and familiarization with the treadmill, participants will walk on the treadmill for 20 minutes total with rest periods as needed. Treadmill speed will be set at each participant's overground comfortable walking speed for the first 5 minutes, provided that they can walk safely. If necessary the speed will be lowered until a safe gait is achieved. After 5 minutes the speed will be incrementally increased by10% each 5 minutes (3 times) as long as a safe gait (i.e., no abnormal vital signs, excessive effort, or loss of balance occurrences) can be maintained. If the gait pattern becomes unsafe or more abnormal the speed will revert to the previous safe speed and be maintained at this level until the end of training session.
Study: NCT01057615

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: 10 fish oil (3.2g EPA + 2.0g DHA) capsules per day for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: 10 fish oil (3.2g EPA + 2.0g DHA) capsules per day for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 2 pharmaceutical grade ascorbic acid (1500mg) capsules per day for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 2 pharmaceutical grade ascorbic acid (1500mg) capsules per day for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil Placebo
Description: 10 placebo fish oil (soy bean oil) capsules per day for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid Placebo
Description: 2 placebo ascorbic acid (sucrose) capsules per day for 3 weeks
Study: NCT03946514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan/hydrochlorothiazide
Description: losartan 100 mg/hydrochlorothiazide 25 mg single-pill combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine/hydrochlorothiazide
Description: amlodipine besylate tablets (5 mg / tablet) + hydrochlorothiazide tablets (25 mg / tablet)
Study: NCT05099913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deanxit
Description: Central neuromodulators was applied in refractory FD patients for different time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deanxit
Description: Central neuromodulators was applied in refractory FD patients for different time
Study: NCT04315103

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP
Description: All the injections were done by the same experienced physician using aseptic procedures.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP
Description: All the injections were done by the same experienced physician using aseptic procedures.
Study: NCT01496534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
Study: NCT00103337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01427192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetazolamide
Description: 250 mg bid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Description: Oxygen deliverded by nasal cannula

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Description: Bi-level non-invasive ventilation via nasal mask

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Room air
Description: Room air applied via sham oxygen concentrator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet (Mannitol) similar to acetazolamide
Study: NCT03038984

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: At Home Screening procedure On demand
Description: Home monitoring is a supportive treatment. Patients are randomized to screen themselves on demand

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: At Home Screening procedure every 3 months
Description: Home monitoring is a supportive treatment. Patients are randomized to screen themselves every 3 months
Study: NCT03327402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP465
Description: SHP465 capsule will be administered at a dose of 6.25 mg, orally once daily for 4 weeks. SHP465 is comprised of sulfate salts of dextroamphetamine and amphetamine, with dextroamphetamine saccharate and amphetamine aspartate monohydrate, which provide a composite enantiomer ratio of 3:1 d-amphetamine to l-amphetamine.
Study: NCT03146832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy (according to habituation approach)
Description: Exposure instruction focuses on fear reduction during exposure sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy (according to inhibitory learning approach)
Description: Exposure instruction focuses on expectation violation during exposure sessions
Study: NCT02724813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Preformance (COOP)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Orientation to Occupational Preformance (COOP)
Study: NCT00494260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Learning and Cognitive Behavioral Therapy (SLCBT)
Description: The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Support (ES)
Description: The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
Study: NCT02900612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water aerobics training.
Description: The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water resistance training.
Description: The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
Study: NCT03709290

Intervention type: RADIATION
Intervention: mri
Description: mri brain \& spinal cord

Intervention type: RADIATION
Intervention: mri
Description: mri brain \& spinal cord
Study: NCT05165953

Intervention type: OTHER
Intervention: no intervention
Description: there was no intervention in the study

Intervention type: OTHER
Intervention: no intervention
Description: there was no intervention in the study

Intervention type: OTHER
Intervention: no intervention
Description: there was no intervention in the study
Study: NCT01657630

Intervention type: DEVICE
Intervention: Accu-Chek Combo System
Description: 12 weeks using the Accu Chek Combo System, which is an insulin pump system that offers a remote control integrating a bolus calculator, a blood glucose meter, data storage and analysis function.
Study: NCT03472573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT02566070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Gastric Feeding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolus Gastric Feeding
Study: NCT02442635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.
Study: NCT00478439

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ZeaVision EyePromise Restore
Description: Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, Zeaxanthin 8mg,mixed tocopherols 6mg, lutein 4mg,
Study: NCT02442635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.
Study: NCT00739895

Intervention type: PROCEDURE
Intervention: Cardiac magnetic Resonance study
Description: follow-up studies

Intervention type: PROCEDURE
Intervention: Blood testing
Description: Blood sample tested for myocardial biomarkers
Study: NCT04542226

Intervention type: DRUG
Intervention: Polyoxidonium
Description: Polyoxidonium (azoximer bromide) is administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections)
Study: NCT00478439

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin
Description: Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, mixed tocopherols 6mg, lutein 4mg,
Study: NCT02751645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Normovolemic hemodilution
Description: ANH is a technique in which a portion of the patients' own blood is removed before any surgical bleeding occurs. It is stored until the end of the operation, at which point it is returned to the patient.
Study: NCT02062281

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trivalent influenza vaccine
Description: Single 0.5ml trivalent influenza vaccine was administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23vPPV+TIV
Description: Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.
Study: NCT04589390

Intervention type: DRUG
Group type: OTHER
Intervention: Selexipag
Description: treatment with selexipag
Study: NCT01150019

Intervention type: OTHER
Intervention: Cross sectional study
Description: This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting

Intervention type: OTHER
Intervention: Cross sectional study
Description: This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
Study: NCT03198936

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cognizin® SynapsaTM
Description: 2 capsules to be taken twice a day with meals with a glassful of water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules to be taken twice a day with meals with glassful of water